News

  • Reset
Financial,Data,Graph,Chart,,Vector,Illustration.,Abstract,Background,With,Graph

Mayne Pharma 2023 Half Year Results Media Release

28 Feb 2023

Mayne Pharma’s CEO, Mr Shawn O'Brien said, “The performance of our business during the first half of FY23 is categorized by building momentum in our Branded Products Division."

Learn more

Capsules

Mayne Pharma announces sale of U.S. Generics Portfolio to Dr. Reddy’s

27 Feb 2023

Mayne Pharma’s CEO Mr. Shawn Patrick O’Brien said: “Divesting the retail generics portfolio is an important step forward for the Company as we continue to rationalise our portfolio. With this transaction, we free up working capital, allowing us to more exclusively focus resources on core areas of value for business growth, namely our branded verticals in US women's health and dermatology."

Learn more

Mayne Pharma signs exclusive license agreement for three women’s health products and a range of prenatal vitamins in the US

5 Dec 2022

Mayne Pharma Group Limited has signed an exclusive license agreement with TherapeuticsMD, Inc. a NASDAQ listed company for three branded women’s health products and a portfolio of prenatal vitamins in the US (License Agreement)

Learn more

Financial,Data,Graph,Chart,,Vector,Illustration.,Abstract,Background,With,Graph

Mayne Pharma to return up to $113m to shareholders

28 Oct 2022

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that following completion of the sale of Metrics Contract Services (Metrics) it intends to return up to $113 million to shareholders, through a combination of cash distributions.

Learn more

Mayne Pharma completes sale of Metrics Contract Services

4 Oct 2022

Mayne Pharma Group Limited is pleased to announce the completion of the sale of Metrics Contract Services (Metrics) to Catalent Pharma Solutions, Inc. for US$475 million (approximately A$722 million at current exchange rates).

Learn more

Mayne Pharma appoints new CEO

28 Sep 2022

Mayne Pharma Group Limited is pleased to announce it has appointed Mr Shawn Patrick O’Brien as Chief Executive Officer and Managing Director effective 1 October 2022. This follows from the previously announced retirement of Mr Scott Richards and a comprehensive search for a successor.

Learn more

Non Executive Director appointment and retirement

31 Aug 2022

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Mr David Petrie, has accepted an invitation to join the Board of Mayne Pharma, effective 1 September 2022.

Learn more

Mayne Pharma 2022 Full Year Results Media Release

26 Aug 2022

Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, we reported annual revenue growth for the first time in five years. Excluding retail generics, the remaining businesses which represent more than 80% of reported gross profit grew 27% on the prior corresponding period (pcp).

Learn more

Mayne Pharma CEO announces plan to retire

19 Aug 2022

Mayne Pharma Group Limited advises that Chief Executive Officer (CEO) Scott Richards has announced his intention to retire following a decision by the Board to relocate the CEO role to the US on a permanent basis. Mr Richards is unable to make this commitment and wants to return to Australia for personal reasons.

Learn more